Status:
COMPLETED
Type 2 Diabetic Patients Maintained on Statin Therapy
Lead Sponsor:
Damanhour University
Collaborating Sponsors:
Tanta University
Conditions:
Dyslipidemia Associated With Type II Diabetes Mellitus
Eligibility:
All Genders
35-70 years
Phase:
PHASE4
Brief Summary
Patients with diabetes mellitus (DM) are at increased risk of atherosclerotic cardiovascular disease (ACVD). The achievement of the LDL-C target with statins for the reduction of ACVD risk is recommen...
Detailed Description
a prospective, double blind trial, conducted between January 2018 and January 2020. Participants were enrolled if they had moderate cardiovascular risk (Framingham risk score of 10-20%), in other word...
Eligibility Criteria
Inclusion
- type II diabetic patients with hypercholesterolemia
Exclusion
- liver impairment,
- renal insufficiency,
- coronary artery disease,
- metabolic disorders,
- type I diabetes,
- autoimmune diseases, cancer, infection,
- use of anti-inflammatory drugs,
- recent major surgery,
- weight-loss or modified anti-hypertensive medications 12 weeks or less prior to enrolment,
- ongoing or previous use of lipid-lowering medications (including other statins, fibric acid derivatives, nicotinic acid, cholestyramine, ezetimibe or omega-3 fatty acids) and contraindications to the use of statins.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2020
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT03784703
Start Date
January 1 2018
End Date
January 31 2020
Last Update
January 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University Hospital
Tanta, El-Gharbia, Egypt, 31527